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Aim. To assess prescribing practices of noninsulin antidiabetic drugs (NIADs) in T2DM with several major contraindications
according to prescribing information or clinical guidelines: renal failure, heart failure, liver dysfunction, or history of bladder
cancer.Methods. Cross-sectional, descriptive, multicenter study. Electronic medical records were retrieved from all T2DM subjects
who attended primary care centers pertaining to the Catalan Health Institute in Catalonia in 2013 and were pharmacologically
treated with any NIAD alone or in combination. Results. Records were retrieved from a total of 255,499 pharmacologically treated
patients. 78% of patients with some degree of renal impairment (glomerular filtration rate (GFR) < 60mL/min) were treated with
metformin and 31.2% with sulfonylureas. Even in the event of severe renal failure (GFR < 30mL/min), 35.3% and 22.5% of patients
were onmetformin or sulfonylureas, respectively.Moreover, metforminwas prescribed tomore than 60% of patients withmoderate
or severe heart failure. Conclusion. Some NIADs, and in particular metformin, were frequently used in patients at high risk of
complications when they were contraindicated. There is a need to increase awareness of potential inappropriate prescribing and
to monitor the quality of prescribing patterns in order to help physicians and policymakers to yield better clinical outcomes in
T2DM.
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1. Introduction
Lifestyle modification, primarily through diet, and exercise
advise are the preferred therapeutic approaches in the initial
treatment of type 2 diabetes mellitus (T2DM). However, the
disease tends to progress andmost patients will be required to
start on oral medication to maintain individualized glycemic
targets. Noninsulin antidiabetic drugs (NIADs) are typically
the first option for initial pharmacotherapy and include
different classes of drugs with diverse modes of action,
therapeutic potency, and adverse reactions [1].
Some NIADs have contraindications or must be used
with caution in patients with T2DM and particular comorbid
conditions. Major at-risk conditions that require tailored
management of hyperglycemia include heart failure, chronic
kidney disease, liver dysfunction, or history of bladder
cancer. Moderate to severe renal impairment, for instance, is
present in 20–40% of T2DM patients [2–4], which requires
careful evaluation of risks and benefits when prescribing
antihyperglycemic drugs with renal clearance. In addition,
the prevalence of chronic heart failure in T2DM is 10–23%,
and they have 2-fold greater risk of heart failure than their
nondiabetic counterparts [5]. Suboptimal glycemic control
is a predictor for its development [6]; furthermore, some
glucose-lowering agents may be associated with an increased
risk of heart failure [7]. Finally, T2DM patients also have an
increased prevalence of the entire spectrum of liver disease,
from abnormal liver enzyme levels to acute liver failure,
and the use of particular antihyperglycemic agents must be
avoided or theymust be usedwith caution due to altered drug
metabolism and/or hepatotoxicity [8].
Besides prescribing information enclosed in the package
insert or the summary of product characteristics (SmPC),
which list the labels and contraindications of each particular
drug, local health authorities, international expert consensus
documents, and clinical guidelines regularly publish recom-
mendations on the use of antidiabetic drugs and indicate in
which comorbid conditions they are formally contraindicated
[9–12].
The appropriate use of NIADs in accordance with pre-
scribing information or recommendations is of great impor-
tance to preserve or increase quality of life, particularly in
patients with comorbid disease conditions [13]. However,
a poor adherence to local and/or international guidelines
on T2DM management has been reported in both primary
and secondary care settings, and inappropriate or potentially
inappropriate prescription of NIADs to patients with a
contraindication or precautionary condition has also been
documented [14–19].
The aim of this study was to investigate prescribing
patterns of NIADs in a primary care setting in Catalonia,
Spain, in patients with some at-risk comorbid conditions and
assessed whether treatment choices agreed with the current
drug’s prescribing information, recommendations of expert
consensus documents, or clinical guidelines when they are
formally contraindicated or recommended to be used with
caution.
2. Methods
2.1. Design. This was a cross-sectional, descriptive, multicen-
ter study including all type 2 diabetes subjects between 31
and 90 years of age who attended any of the 274 primary
care centers pertaining to the Catalan Health Institute (ICS)
in Catalonia, Spain, in 2013. Electronic medical records
were retrieved from the SIDIAP database (System for the
Development of Research in Primary Care) as previously
reported [4, 20]. Subjects were included in the study if they
had a T2DM diagnosis (ICD-10 codes E11, E11.0–E11.9, E14,
or E14.0–E14.9) in the electronic clinical record and were
prescribed pharmacological treatment with any NIAD in
monotherapy or in combination. Those patients exclusively
treated with lifestyle modification or insulin as monotherapy
were excluded.
2.2. Studied Variables. The study included data on age; gen-
der; duration of T2DM; standardized glycated hemoglobin
(HbA1c) values, using the most recent value of the preceding
15 months; and risk factors and diabetic complications,
including body mass index (BMI) (most recent value in
the last 24 months), microvascular complications (diabetic
retinopathy, nephropathy or neuropathy), andmacrovascular
complications (coronary artery disease, recent myocardial
infarction of a duration less than 1 year, stroke, peripheral
artery disease, and heart failure). Pharmacological treatments
were extracted from prescription- and pharmacy-invoicing
data provided by the CatSalut general database and included
the use of any NIADs as monotherapy or in combination
with other glucose-lowering drugs (e.g., insulin) licensed at
that time in Spain, namely, metformin, sulfonylureas, megli-
tinides, alpha-glucosidase inhibitors (AGIs), pioglitazone,
dipeptidyl peptidase-4 inhibitors (DPP-4i), and glucagon-
like peptide-1 receptor agonists (GLP-1ra).
The following major conditions were considered a poten-
tial contraindication for some drugs based on the summary of
product characteristics (SmPC), international expert consen-
sus documents, or clinical guidelines: (i) renal failure, defined
as a glomerular filtration rate (GFR) < 60mL/min/1.73m2,
and severe renal failure (GFR < 30mL/min/1.73m2), esti-
mated with the Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) equation [21]; (ii) liver dysfunction,
defined as hepatic enzymes over 3 times the upper limit
of normal levels (either glutamyl oxaloacetic transaminase
(GOT) or glutamyl pyruvic transaminase (GPT) > 120 IU/L
or gamma-glutamyl transferase (GGT)> 150 IU/L); (iii) heart
failure (globally and New York Heart Association (NYHA)
class III or IV) functional stage [22]; and (iv) history of
bladder cancer.
This study was approved by the Ethics Committee of the
Primary Health Care University Research Institute (IDIAP)
Jordi Gol.
2.3. Statistical Analysis. Descriptive analyses were summa-
rized by mean and standard deviation for continuous vari-
ables and absolute frequency and percentages for categorical
variables. All statistical calculations were performed using
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Table 1: Demographic and clinical characteristics of T2DM patients included in the study.
Characteristic 𝑁 = 255,499
Age, mean (SD), years 68.0 (11.0)
Gender, 𝑛 (%)
Female 114,181 (44.7%)
Male 141,318 (55.3%)
T2DM duration, mean (SD), years 8.0 (5.6)
HbA1c, mean (SD), %∗ 7.3 (1.4)
BMI, mean (SD), kg/m2 30.3 (5.2)
Renal failure (GFR < 60mL/min), 𝑛 (%)† 40,666 (20.1%)
Severe renal failure (GFR < 30mL/min), 𝑛 (%)† 2,014 (1.0%)
Complications, 𝑛 (%)
Patients with registered severe hypoglycemia episodes 463 (0.2%)
Diabetic retinopathy 19,857 (7.8%)
ACR > 300mg/g 6,661 (2.6%)
Diabetic neuropathy 7,509 (2.9%)
Ischemic heart disease 31,145 (12.2%)
Stroke 15,158 (5.9%)
Peripheral artery disease 12,295 (4.8%)
Heart failure 13,276 (5.2%)
Any macrovascular complication 51,007 (20.0%)
Glucose-lowering treatment, alone or in combination, 𝑛 (%)
Metformin 225,753 (88.4%)
Sulfonylureas 79,472 (31.1%)
Meglitinides 16,941 (6.6%)
AGIs 1,877 (0.7%)
Pioglitazone 3,290 (1.3%)
DPP4i 39,682 (15.5%)
GLP-1ra 2,374 (0.9%)
Insulin with a NIAD 46,150 (18.1%)
∗Out of 199,523 patients with available HbA1c records.
†Out of 195,674 patients with available GFR records.
ACR: albumin/creatinin ratio; AGI: alpha-glucosidase inhibitors; BMI: bodymass index; DPP4i: dipeptidyl peptidase-4 (DPP-4) inhibitors; GLP-1ra: glucagon-
like peptide-1 (GLP-1) receptor agonists; GFR: glomerular filtration rate; HbA1c: glycated hemoglobin; NIAD: noninsulin antidiabetic drug; SD: standard
deviation; T2DM: type 2 diabetes mellitus.
StataCorp 2009 (Stata Statistical Software: Release 11. College
Station, TX: StataCorp, LP).
3. Results
Clinical and demographic characteristics of the patients
included in the study are shown in Table 1. Records were
retrieved from a total of 255,499 patients with T2DM who
during 2013 were prescribed antidiabetic pharmacological
treatment based on a NIAD alone or in combination. The
mean age of the patients was 68.0 years (standard deviation
(SD) = 11.0), with a mean duration of T2DM of 8.0 years (SD
= 5.6). The most common NIADs prescribed in pharmaco-
logically treated cases were metformin (in 88.4% of patients),
sulfonylureas (31.1%), and DPP4i (15.5%).
The clinical and demographic characteristics of the
treated patients stratified by the pharmacological class of the
glucose-lowering agent prescribed (alone or in combination)
are shown in Table 2. In general, patients on metformin had
a shorter T2DM duration, lower glycemic levels, a lower
prevalence of renal failure, and fewer diabetic complications
than patients treated with other NAIDs. Conversely, patients
on insulin in combination with a NAIDwere at the other side
of the spectrum and had the longest duration of the disease,
highest HbA1c levels, and the highest rate of all diabetic
complications.
The clinical characteristics of patients with contraindica-
tions and improper use of a NIAD are shown in Supplemen-
tary Table 1, in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/7502489. Patients with a con-
traindication were older and had a longer T2DM duration
than those without a contraindication, but they did show
lower HbA1c values and hence a better glycemic control.
3.1. Prescribing Patterns of NIADs in Patients with Contraindi-
cated Comorbid Conditions. The number of T2DM patients
with major contraindications and NIADs prescribed alone or
in combination is shown in Table 3.
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Figure 1: NIADs prescribed (alone or in combination) stratified by disease stage in patients with some degree of renal failure (GFR <
60mL/min) (percentages are calculated for the total number of patients in each stage). AGI: alpha-glucosidase inhibitors; GLP-1ra: glucagon-
like peptide-1 (GLP-1) receptor agonists; GFR: glomerular filtration rate; DPP4i: dipeptidyl peptidase-4 (DPP-4) inhibitors; NIAD: noninsulin
antidiabetic drugs.
3.1.1. Renal Failure. A total of 40,666 patients (20.1%) had
some degree of renal failure (GFR < 60mL/min). In 78% of
these cases patients were treated with metformin, and 31.2%
were treated with sulfonylureas, both of them theoretically
contraindicated, while other agents were prescribed in less
than 16% of cases. We observed that, even in cases of severe
renal failure (GFR < 30mL/min; 𝑛 = 2,014; 1% of all treated
patients), when they are formally contraindicated, a signifi-
cant proportion of these patients were still on metformin or
sulfonylureas (35.3% and 22.5%, resp.). Based on the degree
of renal impairment (Figure 1), 36% of cases in stage IV
and 31% in stage V were taking metformin, and 24% and
12% of cases in stages IV and V were taking sulfonylureas,
respectively. However, in both stages IV and V the most
frequently prescribed agents were meglitinides (37% and
47%, resp.). Moreover, we also observed that 1% of patients
with severe renal failure were taking AGIs, and 0.4% were
taking GLP-1ra.
3.1.2. Heart Failure. A total of 13,276 patients (5.2%) had
some degree of heart failure (Table 3). Again, metformin was
the most frequently prescribed NIAD, and even in cases of
moderate (class III) and severe (class IV) functional stages
(a total of 1,222 patients), where metformin is formally
contraindicated, it was prescribed in more than 60% of cases
(67.8% in class III and 60.6% in class IV). Conversely, only
6 out of the 1,222 patients were on pioglitazone, which is
also contraindicated in these 2 functional stages. In the less
severe functional stages (classes I and II) only pioglitazone
is contraindicated but was still prescribed in 5 out of the 938
patients in class I (0.5%) and in 14 out of the 2,300 patients in
class II (0.6%) functional stage.
3.1.3. Liver Dysfunction. A total of 1,447 patients had elevated
liver enzymes (liver dysfunction; Table 3). In these cases, the
vast majority of patients were on metformin or sulfonylureas
(78.8% and 27.8%, resp.), which are not necessarily con-
traindicated except in cases of advanced liver failure. How-
ever, a small proportion of patients (0.5%) were prescribed
pioglitazone, which, based on the SmPC, is contraindicated
in patientswith baselineGPT levels>2.5 times the upper limit
of normal.
3.1.4. Bladder Cancer. A history of bladder cancer was
recorded for 3,073 patients (Table 3). Although the vast
majority of these patients where on metformin or sulfony-
lureas, 33 of them (1.1%) were treated with pioglitazone,
which is currently a formal contraindication in this condition.
4. Discussion
In the present study we identified a relatively high proportion
of patients with T2DM and a comorbid disease with NIADs
that are contraindicated or not recommended in cases of renal
failure, heart failure, liver dysfunction, or history of bladder
cancer.
Patients with a contraindication inappropriately taking a
particular NIADwere older and had longer diabetes duration
but had better glycemic control than patients without the
same contraindication. This suggests that in spite of these
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patients being at risk of severe adverse events (e.g., hypo-
glycemia or lactic acidosis), treatment discontinuation could
lead to a worsening of glycemic control, thus requiring a
careful evaluation of the most appropriate NIADs to use in
terms of efficacy and safety.
From our results, metformin, which is widely used as
the initial pharmacological therapy for glycemic control in
T2DM, was the NIAD that accounted for the vast majority
of potentially inappropriate prescribing in patients with a
comorbid disease: it was used in 35.3% of patients with severe
renal failure (GFR < 30mL/min) and in more than 60%
of patients with moderate or severe heart failure. Because
metformin has been associated with a risk of lactic acidosis,
labeling contraindications include these conditions [10, 12,
23], but studies that have evaluated its prescribing pattern
outside clinical recommendations reveal that it is actually
used in a high proportion of cases in whichmajor contraindi-
cations exist and in percentages similar to the figures that
we observed [14–17]. A cross-sectional study conducted in
Germany found that 73% of outpatients who were prescribed
metformin had at least 1 contraindication, risk factors, or
intercurrent illnesses necessitating its discontinuation [14]. A
retrospective population-based study conducted in Scotland
found that in 24.5% of patients who received metformin it
was prescribed in spite of the presence of contraindications,
and only 17.5% and 25% stopped metformin after admission
with acute myocardial infarction and development of renal
impairment, respectively [15]. A retrospective chart review
of outpatients in the US found that about 25% of patients
with 1 or more absolute contraindications (congestive heart
failure or renal insufficiency) were prescribed metformin
[17]. Finally, a retrospective study in Italy found that 60%
of patients with 1 absolute contraindication or precautionary
condition were on metformin at hospital admission, and
in 41% of cases with 1 absolute contraindication it was not
appropriately discontinued [16].
In the particular case of the use of metformin in patients
with kidney disease, it has been consistently shown that
prescribing restrictions, which recommend avoiding its use
in patients with mild or moderate chronic kidney disease, are
not actually followed in real-world practice [24]. Moreover,
the incidence of lactic acidosis among patients on metformin
is very low in stable mild-to-moderate renal dysfunction
and not much different from the rates observed with other
medications or the baseline incidence observed in T2DM [13,
24–26]. This has triggered some clinical guidelines to relax
the cut-off, with current recommendations to stopmetformin
only when eGFR falls to <30mL/min, but to reduce the
dosing or use it with caution when eGFR values are between
45 and 30mL/min [10, 12, 27, 28]. However, if we consider an
eGFR <30mL/min as the absolute contraindication, we still
observed that 35.3% of patients in this stage were prescribed
metformin in our setting, which is strikingly high.
The same trend has been observed with the use of
metformin in patients with heart failure, with recent sys-
tematic reviews and meta-analyses showing that it is a safe
option compared to other NIADs regarding the risk of heart
failure or lactic acidosis [7, 29, 30]. Indeed, based on clinical
evidence and these results, regulatory bodies in the US (Food
and Drug Administration) in 2006 and in Canada (Health
Canada) in 2010 removed the absolute contraindication of
metformin in heart failure from the prescribing information
and replaced it with a black box warning for its use in this
population [31]. However, prescribing information has not
been reviewed or modified in Europe, although the recent
guideline of the European Society of Cardiology recognizes
that they are widely and safely used in patients with heart
failure and only recommends not to use it in case of severe
renal failure or hepatic impairment [32]. Therefore, it seems
reasonable to use metformin when the patient is stable and to
avoid it in case of further impairment or hospitalization, as
recommended by the recent American Diabetes Association
guideline [10]. In our study, the rates of prescription of
metformin in patients with III and IV heart failure functional
stages were 67.8% and 60.6%, respectively. Moreover, we
found that pioglitazone, which is also contraindicated in
moderate or severe heart disease, was still prescribed to these
patients (0.4% and 1% of patients with classes III and IV,
resp.). In addition, the rates of inappropriate prescription of
pioglitazone to patients for whom it is contraindicated in our
study were <1.1% across different comorbidities (e.g., bladder
cancer or liver dysfunction), which is much lower than the
rate previously reported in a study conducted in Taiwan,
which found that thiazolidinediones were inappropriately
prescribed in about 10% of patients [33]. The reasons for this
discrepancy are unclear, but the authors postulated that this
high rate was due to the quick penetration of this drug class
in the local market, while our low percentage could in turn
be linked to a comparatively low penetrance in the Spanish
market.
To our knowledge there are no studies assessing the
rates of inappropriate prescription of sulfonylureas in for-
mal contraindications, but many members of this class are
associated with an increased risk of hypoglycemic episodes
in patients with renal impairment or chronic liver disease
[13]. We found figures that may be considered relatively
high, as they were prescribed to 22.5% of patients with
GFR <30mL/min. In addition, sulfonylureas were prescribed
in 27.8% of patients with liver dysfunction and metformin
in 78.8% of such cases. However, they are only formally
contraindicated in cases of advanced liver failure. Since we
defined liver dysfunction as an elevation of liver enzymes >3
times the upper normal limits and this can be observed across
different liver conditions, these do not actually correspond
to real inappropriate prescriptions except in the case of
pioglitazone (used in 0.5% of patients with liver dysfunction),
which is specifically contraindicated when liver enzymes are
elevated.
The present study has advantages and limitations that
must be acknowledged. The main advantage is that we
used a primary care database with high quality records
that reflects real-life clinical practices in a large population
of T2DM treated patients. However, and inherent to most
retrospective studies, some of the studied variables were not
always properly recorded in themedical records; for instance,
therewere 22%of patients without data onHbA1c values, 33%
without data onGFR, or 66% forwhom theNYHA functional
class was not registered. Moreover, we cannot rule out a poor
8 Journal of Diabetes Research
registration of comorbidities or at-risk conditions that could
have underestimated the results. In addition, the retrospec-
tive design precludes determining whether clinicians were
actually aware that they were prescribing against the label or
clinical guidelines recommendations or the drugs were given
in spite of the contraindication based on weighted individual
risk-benefits. For instance, it is probable that the high rates
of inappropriate or potentially inappropriate prescription of
metformin is partly due to the fact that the risk-benefit in
patients with nonabsolute contraindications favors its use
in terms of the associated reduction of the risk of diabetes
related complications, in particular macrovascular diseases.
Finally, we could not estimate in what proportion of cases the
particular drug was discontinued after the contraindicated
condition developed and the at-risk condition was thus
prevented, and we could not quantify either the incidence
of adverse reactions after an inappropriate prescription (e.g.,
lactic acidosis, severe hypoglycemia episodes, or heart fail-
ure) or whether the drug was discontinued in case of a drug-
related adverse event.
In summary, our results show that some NIADs, and in
particular metformin, are frequently used in patients at high
risk of complications when they are contraindicated or not
recommended by the accompanying prescribing informa-
tion or clinical guidelines. Prescribing of antidiabetic drugs
to unsuitable patients has clinical consequences associated
with an increased risk of adverse reactions and suboptimal
glycemic control, and it is also associated with an economic
impact relative to patients treated according to guidelines
[34–37]. However, current guidelines or expert consensus
does not always give clear recommendations on the use of
specific NIADs in T2DM patients with a comorbid disease,
probably as a result of a lack of clinical trials enrolling high-
risk subjects, which may in turn result in a lack of practical
advice for physicians, facilitating potentially inappropriate
prescribing [13].
5. Conclusions
There is a need to increase awareness of potential inappro-
priate prescribing and to monitor the quality of prescribing
patterns in order to help physicians and policymakers to yield
better clinical outcomes in T2DM. This could be accom-
plished through the implementation of security reminders in
the electronic clinical records so that physicians are aware of
an existing complication that would require dose adjustment,
discontinuing, or not even starting on a particular drug.
Moreover, specific educational programs aimed at reducing
the failure to recognize contraindications in patients with
comorbid conditions and improving knowledge on currently
available pharmaceutical products would be of great benefit
to improve the management of the disease.
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